Thymosin Alpha-1: The Most-Tested Peptide the US Won’t Approve

Thymosin alpha-1 is a naturally occurring 28-amino-acid peptide that the thymus gland produces to help regulate the immune system. It was first isolated and sequenced by Allan Goldstein and colleagues in 1977 from a thymic preparation known as thymosin fraction 5, making it one of the oldest and most thoroughly characterised peptides in immunology.

Its synthetic version is the drug thymalfasin, sold under the brand name Zadaxin. Originally developed by SciClone Pharmaceuticals, Zadaxin became an established commercial product in markets where chronic hepatitis B is common, and the company was eventually acquired in a deal valued at around 605 million dollars. That history matters, because it means thymosin alpha-1 is not a speculative research chemical. It is an approved pharmaceutical in much of the world that simply never secured approval in the United States.

The bottom line: Thymosin alpha-1 is a long-studied thymic immune peptide that exists as a licensed medicine abroad and a research compound in the US.

Thymosin alpha-1 works by tuning the immune response rather than directly attacking pathogens. It acts on both the innate and adaptive arms of immunity, mainly through Toll-like receptor signalling, particularly TLR2 and TLR9, on dendritic cells and other immune cells.

Through that signalling, the peptide promotes the maturation of dendritic cells, supports the differentiation of T cells, and nudges the response toward a T-helper-1 profile, the arm of immunity that handles intracellular threats such as viruses. It also enhances natural killer cell activity and influences cytokine production. The recurring theme across these effects is restoration of balance: thymosin alpha-1 tends to lift host defences in states of immune exhaustion or suppression while tempering excessive inflammation, which is why it has been investigated in conditions as different as chronic viral infection and overwhelming sepsis.

The bottom line: Thymosin alpha-1 is an immune modulator that restores balance through Toll-like receptor signalling, dendritic cell maturation, and a shift toward antiviral immunity.

Thymosin alpha-1 has one of the largest clinical evidence bases of any peptide therapeutic, with more than 11,000 subjects enrolled across over 30 clinical trials and post-marketing surveillance covering hundreds of thousands of treated patients. That volume of data is what separates it from almost every other peptide discussed in the wellness market. The picture it paints, however, is genuinely mixed rather than uniformly positive.

Chronic hepatitis B and C

The hepatitis evidence is the strongest. Multiple randomised controlled trials have shown that thymosin alpha-1, often combined with antiviral therapy, produces delayed but durable virological responses and improves liver outcomes, with a side-effect profile far gentler than interferon. This is the indication that anchored Zadaxin’s international approvals.

Sepsis and critical illness

Here the evidence is more sobering. The TESTS trial, led by Jianfeng Wu and published in the BMJ in 2025, was a multicentre, double-blind, placebo-controlled Phase 3 study enrolling 1,106 sepsis patients, the largest randomised trial of the peptide to date. It did not meet its primary endpoint, meaning the headline mortality benefit researchers hoped to confirm was not demonstrated. That a peptide with this much history failed its biggest rigorous test is exactly the kind of detail that separates honest evidence reporting from marketing.

COVID-19 and cancer support

Interest surged during the pandemic after observational data from Wuhan, reported by Zhang and colleagues in 2020, suggested a possible mortality benefit in severe COVID-19. That signal came from a small, non-randomised cohort and should be read as hypothesis-generating, not confirmatory. In oncology, thymosin alpha-1 has been studied as an add-on to chemotherapy and immunotherapy, with results that vary by cancer type and trial design.

Indication	Evidence tier	What it shows
Chronic hepatitis B	Multiple RCTs	Durable response; basis for global approval
Sepsis	Phase 3 RCT (n=1,106)	Missed primary endpoint (TESTS, BMJ)
COVID-19	Observational	Possible benefit; small, non-randomised
Cancer support	Mixed adjuvant trials	Varies by cancer type and regimen

The bottom line: Thymosin alpha-1 has convincing evidence in chronic hepatitis B, a notable Phase 3 miss in sepsis, and weaker preliminary signals elsewhere.

Thymosin alpha-1 is approved as a prescription medicine in more than 35 countries but has never been approved in the United States, the United Kingdom, or Australia. The US situation is the most consequential, and the most revealing.

The United States: voted down despite the evidence

In the US, an unapproved peptide can only be legally compounded if it qualifies under the bulk-substance rules described in our guide to the three-tier compounding category system. Thymosin alpha-1 was placed in the restricted category in 2023, then removed in September 2024 after its nomination was withdrawn, which sent it to the advisory committee for review. On 4 December 2024 the Pharmacy Compounding Advisory Committee considered thymosin alpha-1 in both its free base and acetate forms and voted against adding it to the 503A list.

What makes that vote striking is that thymosin alpha-1 had the strongest human clinical record of any substance on that docket, yet it was still rejected, with the committee citing concerns about manufacturing characterisation and the adequacy of US-specific data rather than the strength of the global evidence. Crucially, thymosin alpha-1 was not swept up in the much larger 2026 reclassification wave that we map in our timeline of the full sequence of FDA reclassification actions. Its review already happened, and it went the other way. The wider enforcement and import context is covered in our overview of how US law treats unapproved peptides.

United Kingdom and Australia

Thymosin alpha-1 holds no marketing authorisation in Britain and is treated as an unlicensed substance, as explained in our guide to peptide rules across the UK. In Australia it is not entered on the Australian Register of Therapeutic Goods and is therefore not an approved product; the framework is set out in our explainer on how Australia schedules these compounds.

Jurisdiction	Status	Notes
35+ countries	Approved (Zadaxin)	Mainly hepatitis B and immune support
United States	Not approved	Compounding rejected by advisory vote, Dec 2024
United Kingdom	Not approved	No UK marketing authorisation
Australia	Not approved	Not entered on the ARTG

The bottom line: Thymosin alpha-1 is a licensed drug in much of the world, but US compounding access was rejected on advisory review, and it sits outside the 2026 reclassification round entirely.

Across decades of clinical use, thymosin alpha-1 has a reassuring tolerability record. A 2024 comprehensive review of its human clinical trials by Dinetz and Lee concluded that the peptide was safe and well tolerated across the indications studied, with serious adverse events uncommon and the most frequent complaint being mild injection-site reactions. The authors argued that the US restriction looked unsupported by the safety data, a notable position given the regulatory outcome that followed.

Regulators have nonetheless flagged two concerns specific to compounded versions: the potential for immunogenicity depending on the route of administration, and the difficulty of properly characterising a peptide of this length and purity outside an approved manufacturing process. These are quality and manufacturing questions rather than evidence of the molecule being inherently dangerous.

The sourcing problem

Thymosin alpha-1 is a relatively long peptide, and synthesising it correctly is non-trivial; truncated or incorrect sequences are a real failure mode in unregulated production. The pharmaceutical-grade product that exists abroad is a different animal from a research-labelled vial bought online. Anyone evaluating a product should understand reading third-party testing documentation and apply the standards in our guide to judging whether a supplier is trustworthy.

The bottom line: The molecule has a strong safety record, but the regulatory friction is about manufacturing quality and route, not toxicity.

Thymosin alpha-1 is an immune regulator rather than a tissue-repair peptide, which sets it apart from most compounds discussed under the recovery banner in our broader recovery-peptide overview. The closest functional relatives are peptides with immune or anti-inflammatory roles, such as KPV, another anti-inflammatory peptide, and the human cathelicidin LL-37, both of which act on inflammatory and host-defence pathways rather than on tissue regeneration directly.